322 related articles for article (PubMed ID: 31853597)
1. Posterior tibial nerve stimulation for overactive bladder-techniques and efficacy.
Bhide AA; Tailor V; Fernando R; Khullar V; Digesu GA
Int Urogynecol J; 2020 May; 31(5):865-870. PubMed ID: 31853597
[TBL] [Abstract][Full Text] [Related]
2. Posterior tibial nerve stimulation vs parasacral transcutaneous neuromodulation for overactive bladder in children.
Barroso U; Viterbo W; Bittencourt J; Farias T; Lordêlo P
J Urol; 2013 Aug; 190(2):673-7. PubMed ID: 23422257
[TBL] [Abstract][Full Text] [Related]
3. Shifts in patient preference of third-line overactive bladder therapy after introduction of the implantable tibial nerve stimulator.
Kapur A; Aalami Harandi A; Hartman-Kenzler J; Kim J
Neurourol Urodyn; 2024 Apr; 43(4):959-966. PubMed ID: 38390786
[TBL] [Abstract][Full Text] [Related]
4. Tibial nerve stimulation for overactive bladder syndrome unresponsive to medical therapy.
Ridout AE; Yoong W
J Obstet Gynaecol; 2010 Feb; 30(2):111-4. PubMed ID: 20143965
[TBL] [Abstract][Full Text] [Related]
5. Cost of neuromodulation therapies for overactive bladder: percutaneous tibial nerve stimulation versus sacral nerve stimulation.
Martinson M; MacDiarmid S; Black E
J Urol; 2013 Jan; 189(1):210-6. PubMed ID: 23174264
[TBL] [Abstract][Full Text] [Related]
6. Management of Idiopathic Overactive Bladder Syndrome: What Is the Optimal Strategy After Failure of Conservative Treatment?
Marcelissen T; Cornu JN; Antunes-Lopes T; Geavlete B; Delongchamps NB; Rashid T; Rieken M; Rahnama'i MS
Eur Urol Focus; 2018 Sep; 4(5):760-767. PubMed ID: 29807823
[TBL] [Abstract][Full Text] [Related]
7. Tibial Nerve Stimulation for Urge Urinary Incontinence and Overactive Bladder: Narrative Review of Randomized Controlled Trials and Applicability to Implantable Devices.
Lee UJ; MacDiarmid S; Matthews CA; Gillespie E; Peters KM
Adv Ther; 2024 Jul; 41(7):2635-2654. PubMed ID: 38748331
[TBL] [Abstract][Full Text] [Related]
8. Percutaneous tibial nerve stimulation for the long-term treatment of overactive bladder: 3-year results of the STEP study.
Peters KM; Carrico DJ; Wooldridge LS; Miller CJ; MacDiarmid SA
J Urol; 2013 Jun; 189(6):2194-201. PubMed ID: 23219541
[TBL] [Abstract][Full Text] [Related]
9. The management of overactive bladder: percutaneous tibial nerve stimulation, sacral nerve stimulation, or botulinum toxin?
Tubaro A; Puccini F; De Nunzio C
Curr Opin Urol; 2015 Jul; 25(4):305-10. PubMed ID: 26049873
[TBL] [Abstract][Full Text] [Related]
10. Outcomes following percutaneous tibial nerve stimulation (PTNS) treatment for neurogenic and idiopathic overactive bladder.
Tudor KI; Seth JH; Liechti MD; Ochulor J; Gonzales G; Haslam C; Fox Z; Pakzad M; Panicker JN
Clin Auton Res; 2020 Feb; 30(1):61-67. PubMed ID: 30074101
[TBL] [Abstract][Full Text] [Related]
11. Tibial nerve stimulation in the treatment of overactive bladder syndrome: technical features of latest applications.
Te Dorsthorst M; van Balken M; Heesakkers J
Curr Opin Urol; 2020 Jul; 30(4):513-518. PubMed ID: 32452995
[TBL] [Abstract][Full Text] [Related]
12. Comparing the Efficacy of OnabotulinumtoxinA, Sacral Neuromodulation, and Peripheral Tibial Nerve Stimulation as Third Line Treatment for the Management of Overactive Bladder Symptoms in Adults: Systematic Review and Network Meta-Analysis.
Lo CW; Wu MY; Yang SS; Jaw FS; Chang SJ
Toxins (Basel); 2020 Feb; 12(2):. PubMed ID: 32085542
[TBL] [Abstract][Full Text] [Related]
13. Randomized trial of percutaneous tibial nerve stimulation versus Sham efficacy in the treatment of overactive bladder syndrome: results from the SUmiT trial.
Peters KM; Carrico DJ; Perez-Marrero RA; Khan AU; Wooldridge LS; Davis GL; Macdiarmid SA
J Urol; 2010 Apr; 183(4):1438-43. PubMed ID: 20171677
[TBL] [Abstract][Full Text] [Related]
14. [Neuromodulation as a treatment for overactive bladder syndrome].
Smits MA; Marcelissen TA; van Kerrebroeck PE; de Wachter SG
Ned Tijdschr Geneeskd; 2012; 156(33):A4135. PubMed ID: 22894803
[TBL] [Abstract][Full Text] [Related]
15. What Is the Role of Additional Pharmacotherapy and Neuromodulation in Patients with Marginal Benefit from Botulinum Toxin Injection?
Zahner PM; Giusto LL; Goldman HB
Curr Urol Rep; 2018 Sep; 19(11):91. PubMed ID: 30196438
[TBL] [Abstract][Full Text] [Related]
16. Cost-effectiveness of novel therapies for overactive bladder.
Mayr CA; Shepherd JP
Expert Rev Pharmacoecon Outcomes Res; 2014 Aug; 14(4):527-35. PubMed ID: 24809616
[TBL] [Abstract][Full Text] [Related]
17. Sacral neuromodulation in patients with idiopathic overactive bladder after initial botulinum toxin therapy.
Smits MA; Oerlemans D; Marcelissen TA; Van Kerrebroeck PE; De Wachter SG
J Urol; 2013 Dec; 190(6):2148-52. PubMed ID: 23872028
[TBL] [Abstract][Full Text] [Related]
18. [Treatment for refractory non-neurogenic overactive bladder].
Gamé X; Phé V
Prog Urol; 2020 Nov; 30(14):920-930. PubMed ID: 33220820
[TBL] [Abstract][Full Text] [Related]
19. Efficacy of transcutaneous stimulation of the posterior tibial nerve compared to percutaneous stimulation in idiopathic overactive bladder syndrome: Randomized control trial.
Ramírez-García I; Blanco-Ratto L; Kauffmann S; Carralero-Martínez A; Sánchez E
Neurourol Urodyn; 2019 Jan; 38(1):261-268. PubMed ID: 30311692
[TBL] [Abstract][Full Text] [Related]
20. Neuromodulation in urology, state of the art.
Ammirati E; Giammò A; Manassero A; Carone R
Urologia; 2019 Nov; 86(4):177-182. PubMed ID: 31368415
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
